EANS-News: Epigenomics Signs Distribution Deal with Pronto Diagnostics for Epi proColon in Israel

Epigenomics expands commercial reach for CE-marked product beyond
home market

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Company Information/Molecular diagnostics

Subtitle: Epigenomics expands commercial reach for CE-marked product
beyond home market

Berlin, Germany, and Tel Aviv, Israel, October 14, 2010 (euro adhoc)
- Epigenomics AG (Frankfurt Prime Standard: ECX) and Pronto
Diagnostics Ltd. today announced that they have signed an exclusive
distributor agreement for the commercialization of Epigenomics' Epi
proColon test in Israel.

Epi proColon is the world's first CE-marked molecular diagnostic test
for the early detection of colorectal cancer in blood. The test is
based on Epigenomics' proprietary biomarker Septin9. Pronto
Diagnostics expects to begin marketing the test in Israel in November
2010.

Colorectal cancer is one of the most prevalent cancers in Israel with
3,200 new patients diagnosed each year (Israel Cancer Association).
Everyone over the age of 50 is recommended to be tested for
colorectal cancer every two years. Colorectal cancer is curable and
patients diagnosed with it have a good chance of recovery provided
that the cancer is detected early enough when it is still in the
localized stages.

"Epi proColon facilitates the early detection for colorectal cancer
making diagnosis easier and more patient-friendly than ever," Dr. Nir
Navot, Chief Executive Officer of Pronto Diagnostics explained. "This
test can be performed along with other routine blood tests and does
not require any preparation of the screened individual. We expect
that a significantly higher number of people will be prepared to
undergo screening for colorectal cancer with this new test than with
current methods such as stool tests and colonoscopy alone."

Epi proColon is currently marketed by Epigenomics directly in
Germany, Austria and Switzerland. Outside this home market, it is
Epigenomics' strategy to make the CE-marked test broadly available
through a mix of direct commercialization and a distributor network.

"We are delighted to have signed-up Pronto Diagnostics as our
exclusive Israeli distributor for Epi proColon. The team at Pronto
Diagnostics has exactly the expertise and experience we were looking
for," commented Geert Nygaard, Chief Executive Officer of
Epigenomics. "With this agreement we have begun expanding our
commercial reach beyond the home market. We will continue this
expansion and expect to enter into distribution agreements for
further regions in the near future."

Contact Pronto Diagnostics Ltd.

Aviv Salhov
VP Marketing & Operations
Pronto Diagnostics Ltd.
Tel: 972-73-212 6155
aviv@prontodiagnostics.com
www.prontodiagnostics.com

Contact Epigenomics AG

Dr. Achim Plum
Sen. VP Corporate Development
Epigenomics AG
Tel +49 (0) 30 24345 368
pr@epigenomics.com
www.epigenomics.com

About Epigenomics

Epigenomics is a molecular diagnostics company with a focus on the
development of novel products for cancer. Using DNA methylation
biomarkers, Epigenomics' tests on the market and in development aim
at detecting cancer before symptoms occur and thereby potentially
reducing mortality from this disease.

Epigenomics' product portfolio contains the CE-marked IVD test Epi
proColon, the world's first regulatory cleared molecular diagnostic
test for the detection of colorectal cancer in blood that is based on
the biomarker Septin9, and further proprietary DNA methylation
biomarkers and IVD products at various stages of development and
commercialization for colorectal, lung and prostate cancer. For
development and global commercialization of IVD test products,
Epigenomics pursues a dual business strategy in which direct
commercialization of proprietary diagnostic test products is combined
with non-exclusive licensing to diagnostic industry players with
broad customer access. Strategic diagnostics industry partners
include Abbott Molecular, Sysmex Corporation, Quest Diagnostics
Incorporated, and ARUP Laboratories, Inc. for diagnostics test
products and services, and QIAGEN N.V. for sample preparation
solutions and research products. The company is headquartered in
Berlin, Germany, and has a wholly owned subsidiary, Epigenomics Inc.,
in Seattle, WA, USA. For more information, please visit Epigenomics'
website at www.epigenomics.com.

About Pronto Diagnostics

Pronto Diagnostics is a leading provider of molecular diagnostic
products with extensive knowledge, experience, and R&D capabilities
in SNP-based analysis of genetic variations. The company specializes
in developing and marketing diagnostic kits for clinical diagnosis of
genetic disease, carrier screening, prenatal testing, disease
predisposition, and differential diagnosis and is active in the
rapidly growing field of pharmacogenetics and personalized medicine.
For more information see www.prontodiagnostics.com

Notes for editors

Epi proColon

Epi proColon, developed by Epigenomics, detects the methylated DNA of
the Septin9 gene in blood plasma. This Septin9 biomarker has been
shown in numerous clinical studies to be closely associated with the
presence of colorectal cancer and may aid in the detection of this
common cancer. Septin9 is one of the best and most systematically
validated biomarkers for the early detection of colorectal cancer
today. In particular, the recent PRESEPT Study was a successful
prospective evaluation of Epi proColon detection of methylated
Septin9 in a cohort of about 8,000 individuals representative of a
typical screening population.

Epigenomics' legal disclaimers. This communication expressly or
implicitly contains certain forward-looking statements concerning
Epigenomics AG and its business. Such statements involve certain
known and unknown risks, uncertainties and other factors which could
cause the actual results, financial condition, performance or
achievements of Epigenomics AG to be materially different from any
future results, performance or achievements expressed or implied by
such forward-looking statements. Epigenomics AG is providing this
communication as of this date and does not undertake to update any
forward-looking statements contained herein as a result of new
information, future events or otherwise.

The information contained in this communication does not constitute
nor imply an offer to sell or transfer any product, and no product
based on this technology is currently available for sale by
Epigenomics in the United States of America. The analytical and
clinical performance characteristics of any product based on this
technology which may be sold at some future time in the USA have not
been established.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Epigenomics AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Epigenomics AG

Dr. Achim Plum

Sen. VP Corporate Development

Tel: +49 30 24345 368

achim.plum@epigenomics.com

Branche: Biotechnology
ISIN: DE000A0BVT96
WKN: A0BVT9
Index: Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Stuttgart / free trade
Düsseldorf / free trade
München / free trade